scholarly journals Combination versus sequential single agent chemotherapy in advanced breast cancer: associations with metastatic sites and long-term survival

1989 ◽  
Vol 59 (2) ◽  
pp. 227-230 ◽  
Author(s):  
RT Chlebowski ◽  
RV Smalley ◽  
JM Weiner ◽  
LE Irwin ◽  
AA Bartolucci ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Advanced Breast Cancer ◽  
Single Agent ◽  
Advanced Breast ◽  
Term Survival ◽  
Long Term Survival ◽  
Metastatic Sites ◽  
Single Agent Chemotherapy

scholarly journals Long-Term Survival of Women with Locally Advanced Breast Cancer with ≥10 Involved Lymph Nodes at Diagnosis

2014 ◽  
Vol 15 (8) ◽  
pp. 3435-3441 ◽  
Author(s):  
Simon Blechman Zeichner ◽  
Ludimila Cavalcante ◽  
Gabriel Pius Suciu ◽  
Ana Lourdes Ruiz ◽  
Alicia Hirzel ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Lymph Nodes ◽  
Advanced Breast Cancer ◽  
Locally Advanced Breast Cancer ◽  
Locally Advanced ◽  
Advanced Breast ◽  
Term Survival ◽  
Long Term Survival

scholarly journals Sequential dose-dense single agent chemotherapy for locally advanced breast cancer

2003 ◽  
Vol 11 (3) ◽  
pp. 149-149
Author(s):  
Svetislav Vrbic ◽  
Ivica Pejcic ◽  
Sladjana Filipovic ◽  
Stojan Radic
Keyword(s):  
Breast Cancer ◽  
Advanced Breast Cancer ◽  
Locally Advanced Breast Cancer ◽  
Single Agent ◽  
Locally Advanced ◽  
Conservative Surgery ◽  
Advanced Breast ◽  
Dose Dense ◽  
Novel Concept ◽  
Single Agent Chemotherapy

Chemotherapy of breast cancer is still the area of intensive research. Based on mathematical model of tumor cell growth kinetics, articulated by Larry Norton, novel concept of chemotherapy in breast cancer was launched and it implies dose-densification of chemotherapy trough the use of sequential non cross-resistant single agents or regimens. The introduction of primary systemic chemotherapy (PST) improved the outcome of patients with locally advanced breast cancer (LABC). Simultaneous PST is the standard approach to patients with LABC nowadays. On the other hand, many studies using two most active cytotoxic drugs in primary breast cancer, anthracyclines and taxanes showed that sequential dose-dense single agent PST could be superior in terms of enhancing the rates of patients suitable for conservative surgery. In the light of this data, based on the results of the new clinical trials we will discuss merits and demerits of using sequential dose-dense single agent chemotherapy in LABC.

Sign in / Sign up

Export Citation Format

Share Document